Cite
Design, synthesis, and biological evaluation of some 2-(3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-yl)-N-phenylacetamide hybrids as MTDLs for Alzheimer's disease therapy.
MLA
Waiker, Digambar Kumar, et al. “Design, Synthesis, and Biological Evaluation of Some 2-(3-Oxo-5,6-Diphenyl-1,2,4-Triazin-2(3H)-Yl)-N-Phenylacetamide Hybrids as MTDLs for Alzheimer’s Disease Therapy.” European Journal of Medicinal Chemistry, vol. 271, May 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejmech.2024.116409.
APA
Waiker, D. K., Verma, A., Gajendra, T. A., Namrata, Roy, A., Kumar, P., Trigun, S. K., Srikrishna, S., Krishnamurthy, S., Davisson, V. J., & Shrivastava, S. K. (2024). Design, synthesis, and biological evaluation of some 2-(3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-yl)-N-phenylacetamide hybrids as MTDLs for Alzheimer’s disease therapy. European Journal of Medicinal Chemistry, 271, N.PAG. https://doi.org/10.1016/j.ejmech.2024.116409
Chicago
Waiker, Digambar Kumar, Akash Verma, T.A. Gajendra, Namrata, Anima Roy, Pradeep Kumar, Surendra Kumar Trigun, et al. 2024. “Design, Synthesis, and Biological Evaluation of Some 2-(3-Oxo-5,6-Diphenyl-1,2,4-Triazin-2(3H)-Yl)-N-Phenylacetamide Hybrids as MTDLs for Alzheimer’s Disease Therapy.” European Journal of Medicinal Chemistry 271 (May): N.PAG. doi:10.1016/j.ejmech.2024.116409.